➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Colorcon
Medtronic
AstraZeneca
Baxter

Last Updated: July 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,906,890


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,906,890 protect, and when does it expire?

Patent 8,906,890 protects ANGELIQ and is included in one NDA.

This patent has twenty-two patent family members in seventeen countries.

Summary for Patent: 8,906,890
Title:Very low-dosed solid oral dosage forms for HRT
Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.
Inventor(s): Mletzko; Stephan (Berlin, DE), Schurmann; Rolf (Teltow, DE), Gude; Kerstin (Birkenwerder, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:13/087,701
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Drugs Protected by US Patent 8,906,890

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare ANGELIQ drospirenone; estradiol TABLET;ORAL 021355-001 Feb 29, 2012 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,906,890

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10160072Apr 15, 2010

International Family Members for US Patent 8,906,890

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 080912 ⤷  Free Forever Trial
Australia 2011240102 ⤷  Free Forever Trial
Brazil 112012026115 ⤷  Free Forever Trial
Canada 2795801 ⤷  Free Forever Trial
China 102985070 ⤷  Free Forever Trial
Colombia 6630107 ⤷  Free Forever Trial
Costa Rica 20120523 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Baxter
Boehringer Ingelheim
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.